Yoong K F, Afford S C, Jones R, Aujla P, Qin S, Price K, Hubscher S G, Adams D H
Liver Research Laboratories, The MRC Centre for Immune Regulation, The University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TH, UK.
Hepatology. 1999 Jul;30(1):100-11. doi: 10.1002/hep.510300147.
Chemotactic cytokines (chemokines) play an important role in the recruitment of lymphocytes to tissue by regulating cellular adhesion and transendothelial migration. This study examined the expression and function of CXC (human monokine induced by gamma-interferon [HuMig], interleukin-8 [IL-8], and interferon-inducible protein-10 [IP-10]) and CC (macrophage inflammatory protein-1alpha [MIP-1alpha], MIP-1beta, regulated upon activation normal T lymphocyte expressed and secreted (RANTES), and macrophage chemoattractant protein-1 [MCP-1]) chemokines and their respective receptors on lymphocytes infiltrating human liver tumors. Chemokine and chemokine receptor expression was assessed by immunohistochemistry, flow cytometry, in situ hybridization and ribonuclease (RNAse) protection assays and function by in vitro chemotaxis of tumor-derived lymphocytes to purified chemokines and to HepG2 tumor cell culture supernatants. Tumor-derived lymphocytes showed strong chemotactic responses to both CC and CXC chemokines in vitro and expressed high levels of CXCR3 (HuMig and IP-10 receptor) and CCR5 (RANTES, MIP-1alpha, and MIP-1beta receptor). Expansion of tumor-derived lymphocytes in recombinant IL-2 increased expression of CXCR3. The corresponding chemokines were detected on vascular endothelium (HuMig, IL-8, MIP-1alpha, and MIP-1beta) and sinusoidal endothelium (HuMig, MIP-1alpha, MIP-1beta) in hepatocellular carcinoma. In vitro, HepG2 cells secreted functional chemotactic factors for tumor-derived lymphocytes that could be inhibited using anti-CCR5 or anti-CXCR3 monoclonal antibodies (MoAbs). Thus, lymphocytes infiltrating human liver tumors express receptors for and respond to both CXC and CC chemokines. The relevant chemokine ligands are expressed in hepatocellular carcinoma (HCC), particularly HuMig, which was strongly expressed by tumor endothelium, suggesting that they play a role in lymphocyte recruitment to these tumors in vivo. The ability of HepG2 cells to secrete lymphocyte chemotactic factors in vitro suggests that the tumor contributes to lymphocyte recruitment in vivo.
趋化细胞因子(趋化因子)通过调节细胞黏附和跨内皮迁移,在淋巴细胞募集至组织的过程中发挥重要作用。本研究检测了CXC(γ-干扰素诱导的人单核因子[HuMig]、白细胞介素-8[IL-8]和干扰素诱导蛋白-10[IP-10])和CC(巨噬细胞炎性蛋白-1α[MIP-1α]、MIP-1β、活化正常T淋巴细胞表达和分泌调节因子[RANTES]以及巨噬细胞趋化蛋白-1[MCP-1])趋化因子及其各自受体在浸润人肝肿瘤的淋巴细胞上的表达和功能。通过免疫组织化学、流式细胞术、原位杂交和核糖核酸酶(RNAse)保护试验评估趋化因子和趋化因子受体的表达,并通过肿瘤来源淋巴细胞对纯化趋化因子和HepG2肿瘤细胞培养上清液的体外趋化作用评估其功能。肿瘤来源淋巴细胞在体外对CC和CXC趋化因子均表现出强烈的趋化反应,并高表达CXCR3(HuMig和IP-10受体)和CCR5(RANTES、MIP-1α和MIP-1β受体)。重组IL-2中肿瘤来源淋巴细胞的扩增增加了CXCR3的表达。在肝细胞癌中,相应的趋化因子在血管内皮(HuMig、IL-8、MIP-1α和MIP-1β)和肝血窦内皮(HuMig、MIP-1α、MIP-1β)上被检测到。在体外,HepG2细胞分泌对肿瘤来源淋巴细胞有功能的趋化因子,使用抗CCR5或抗CXCR3单克隆抗体(MoAbs)可抑制这些趋化因子。因此,浸润人肝肿瘤的淋巴细胞表达CXC和CC趋化因子的受体并对其产生反应。相关趋化因子配体在肝细胞癌(HCC)中表达,尤其是HuMig,其在肿瘤内皮中强烈表达,提示它们在体内淋巴细胞募集至这些肿瘤的过程中发挥作用。HepG2细胞在体外分泌淋巴细胞趋化因子的能力表明肿瘤在体内有助于淋巴细胞的募集。